Seagen to highlight research in urothelial and colorectal cancers at 2022 european society for medical oncology (esmo) congress

Bothell, wash.--(business wire)--seagen inc. (nasdaq:sgen) today announced upcoming presentations of new data from its clinical development programs at the european society for medical oncology (esmo) congress 2022, to be held september 9-13 in paris, france. one of two late-breaking oral presentations will feature results from cohort k of ev-103 (also known as keynote-869), a phase 1b/2 clinical trial conducted in partnership with astellas. cohort k is evaluating padcev® (enfortumab vedotin-ej
SGEN Ratings Summary
SGEN Quant Ranking